Peptide binding the KLVFF-sequence of amyloid-β

Details Peptide binding the KLVFF-sequence of amyloid-β Peptide binding the KLVFF-sequence of amyloid-β

2007-10-30

2007-10-30

Borin, Michael (Department: 1631)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S017400, C514S002600, C530S328000, C530S329000

Reexamination Certificate

active

10721774

ABSTRACT:
The invention relates to compounds of formula (I) or (II), which are of interest especially for inhibition of polymerization of amyloid β peptide, as model substances for synthesis of amyloid β peptide-ligands, as tools for the identification of other organic compounds with similar functional properties and/or as ligands for detection of amyloid deposits using e.g., positron emission tomography (PET). Formula (II) is: R1-A′-Y′-Leu-X′-Z′-B′-R2in which X′ means any group or amino acid imparting to the compound according to formula (I) the ability to bind to the KLVFF-sequence in amyloid β peptide, or two amino acids imparting the same ability, but with the proviso that one is not proline; Y′ means any amino acid; Z′ means any non-acidic amino acid; A′ means a direct bond or an α-amino acid bonded at the carboxyl terminal of the α-carboxy group or a di-, tri-, tetra- or pentapeptide bonded at the carboxyl terminal of the α-carboxy group; B′ means a direct bond or an α-amino acid bonded at the α-nitrogen or a di-, tri, tetra- or pentapeptide bonded at the α-nitrogen of the N-terminal α-amino acid; R1is H or —CO—R3bonded at the α-amino group of A′; R2is H, —OR4or NR5R6, all bonded to the α-carboxyl group of the α-carboxyterminal of B′; R3and R4are straight or branched carbon chain of 1-4 carbon atoms; R5and R6are independently H, alkyl, cycloalyl, aryl or substituted aryl or together are —(CH2)n— where n is 4-5; and R1and R2together can form a hydrocarbon ring or heterocyclic ring; all α-amino acids being either D- or L-isomers.

REFERENCES:
patent: 4116768 (1978-09-01), Isowa et al.
patent: 5002872 (1991-03-01), Gross
patent: 5470951 (1995-11-01), Roberts
patent: 5514548 (1996-05-01), Krebber et al.
patent: 5578451 (1996-11-01), Nishimoto
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5652334 (1997-07-01), Roberts
patent: 5688651 (1997-11-01), Solomon
patent: 5721130 (1998-02-01), Seubert et al.
patent: 5753624 (1998-05-01), McMichael et al.
patent: 5780587 (1998-07-01), Potter
patent: 5817626 (1998-10-01), Findeis et al.
patent: 5837672 (1998-11-01), Schenk et al.
patent: 5851996 (1998-12-01), Kline
patent: 5854204 (1998-12-01), Findeis et al.
patent: 5854215 (1998-12-01), Findeis et al.
patent: 5869093 (1999-02-01), Weiner et al.
patent: 5891991 (1999-04-01), Wasco et al.
patent: 5985242 (1999-11-01), Findeis et al.
patent: 6022859 (2000-02-01), Kiessling et al.
patent: 6114133 (2000-09-01), Seubert et al.
patent: 6261569 (2001-07-01), Comis et al.
patent: 6277826 (2001-08-01), Findeis et al.
patent: 6303567 (2001-10-01), Findeis et al.
patent: 6319498 (2001-11-01), Findeis et al.
patent: 6331440 (2001-12-01), Nordstedt et al.
patent: 6436903 (2002-08-01), Clayberger et al.
patent: 6610658 (2003-08-01), Findeis et al.
patent: 6670399 (2003-12-01), Green et al.
patent: 6689752 (2004-02-01), Findeis et al.
patent: 6710226 (2004-03-01), Schenk
patent: 6743427 (2004-06-01), Schenk
patent: 6750324 (2004-06-01), Schenk et al.
patent: 6761888 (2004-07-01), Schenk et al.
patent: 6787138 (2004-09-01), Schenk
patent: 6787139 (2004-09-01), Schenk
patent: 6787140 (2004-09-01), Schenk
patent: 6787143 (2004-09-01), Schenk
patent: 6787144 (2004-09-01), Schenk
patent: 6787523 (2004-09-01), Schenk
patent: 6787637 (2004-09-01), Schenk
patent: 6808712 (2004-10-01), Schenk
patent: 6818218 (2004-11-01), Schenk
patent: 6831066 (2004-12-01), Findeis et al.
patent: 6866849 (2005-03-01), Schenk
patent: 6866850 (2005-03-01), Schenk
patent: 6875434 (2005-04-01), Schenk
patent: 7060670 (2006-06-01), Chalifour et al.
patent: 2004/0157781 (2004-08-01), Nordstedt et al.
patent: 2005/0090439 (2005-04-01), Chalifour et al.
patent: 2006/0199771 (2006-09-01), Chalifour et al.
patent: 199870091 (1998-07-01), None
patent: 0584452 (1994-03-01), None
patent: 0752886 (1998-01-01), None
patent: 0584452 (2002-07-01), None
patent: WO 94/05311 (1994-03-01), None
patent: WO 94/14836 (1994-07-01), None
patent: WO 94/19692 (1994-09-01), None
patent: WO 95/05393 (1995-02-01), None
patent: WO 95/05849 (1995-03-01), None
patent: WO 95/08999 (1995-04-01), None
patent: WO 95/12815 (1995-05-01), None
patent: WO 95/23166 (1995-08-01), None
patent: WO 95/31966 (1995-11-01), None
patent: WO 96/13583 (1996-05-01), None
patent: WO 96/28471 (1996-09-01), None
patent: WO 96/34887 (1996-11-01), None
patent: WO 96/37621 (1996-11-01), None
patent: WO 96/39834 (1996-12-01), None
patent: WO 97/08320 (1997-03-01), None
patent: WO 97/21728 (1997-06-01), None
patent: WO 97/32017 (1997-09-01), None
patent: WO 98/02462 (1998-01-01), None
patent: WO 98/05350 (1998-02-01), None
patent: WO 98/08868 (1998-03-01), None
patent: WO 98/22120 (1998-05-01), None
patent: WO 99/06587 (1999-02-01), None
patent: WO 99/27944 (1999-06-01), None
patent: WO 99/27949 (1999-06-01), None
patent: WO 99/58564 (1999-11-01), None
patent: WO 99/60021 (1999-11-01), None
patent: WO 99/60024 (1999-11-01), None
patent: WO 00/20027 (2000-04-01), None
patent: WO 00/26238 (2000-05-01), None
patent: WO 00/43039 (2000-07-01), None
patent: WO 00/52048 (2000-09-01), None
patent: WO 00/68263 (2000-11-01), None
patent: WO 00/72880 (2000-12-01), None
patent: WO 01/39796 (2001-06-01), None
Camilleri et al., “β-Cyclodextrin Interacts with the Alzheimer Amyloid β-A4 Peptide,” FEBS Letters 341:256-258, 1994.
Fraser et al., “Effects of Sulfate Ions on Alzheimer β/A4 Peptide Assemblies: Implications for Amyloid Fibril-Proteoglycan Interactions,” J. Neurochem. 59:1531-1540, 1992.
Lorenzo et al., “β-Amyloid Neurotoxicity Requires Fibril Formation and is Inhibited by Congo Red,” Proc. Natl. Acad. Sci. USA 91:12243-12247, 1994.
Wood et al., “Prolines and Amyloidogenicity in Fragments of the Alzheimer's Peptide β/A4,” Biochem. 34:724-730, 1995.
Tjernberg et al., “Arrest of β-Amyloid Fibril Formation by a Pentapeptide Ligand”, J. Biol. Chem., 1996, pp. 8545-8548, vol. 271, No. 15, The American Society for Biochemistry and Molecular Biology, Inc., Baltimore, Maryland, USA.
Findeis et al., “Modified-Peptide Inhibitors of Amyloid β-Peptide Polymerization,” Biochem. 38:6791-6800, 1999.
Tjernberg et al., “Controlling Amyloid β-Peptide Fibril Formation with Protease-Stable Ligands,” J. Biol. Chem. 272:12601-12605, 1997.
Alberts, “Molecular Biology of the Cell,” Garland Publishing, p. 54, 1989.
Bard et al., “Peripherally Administered Antibodies Against Amyloid β-Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease, ”Nature Med.6(8):916-919, 2000.
Benkirane et al., “Antigenicity and Immunogenicity of Modified Synthetic Peotides Containing D-Amino Acid Residues, ”J. Biol. Chem.268(35):26278-26285, 1993.
Chen et al., “Neurodegenerative Alzheimer-Like Pathology in PDAPP 717V->F Transgenic Mice, ”Prog. Brain Res.117:327-334, 1998.
Cribbs et al., “All-D-Enantiomers of β-Amyloid Exhibit Similar Biological Properties to All-L-β-Amyloids, ”J. Biol Chem.272(11):7431-7436, 1997.
DeMattos et al., “Peripheral Anti-AβAntibody Alters CNS and Plasma Aβ Clearance and Decreases Brain Aβ Burden in a Mouse Model of Alzheimer's Disease, ”Proc. Nat. Acad. Sci. U.S.A.98(15):8850-8855, 2001.
Findels et al., “Modified-Peptide Inhibitors of Amyloid β-Peptide Polymerization, ”Biochemistry38(21):6791-6800, 1999.
Flood et al., “Topography of a Binding Site for Small Amnestic Peptides Deduced from Structure-Activity Studies: Relation to Amnestic Effect of Amyloid β Protein, ”Proc. Nat. Acad. Sci. U.S.A.91:380-384, 1994.
Frenkel, “Generation of Auto-Antibodies Towards Alzheimer's Disease Vaccination, ”Vaccine19(17-19):2615-2619, 2001.
Frenkel et al., “Immuniza

Affiliated with

Also associated with

Rating

Peptide binding the KLVFF-sequence of amyloid-β does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide binding the KLVFF-sequence of amyloid-β, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide binding the KLVFF-sequence of amyloid-β will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3853920